Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-07-15
EX-99.1
This exhibit is a press release announcing drill results from Scorpio Gold's Phase Two exploration program at the Manhattan District Project in Nevada. The disclosure reports assay results from 18 drill holes with significant gold intercepts, including the headline result of "2.05 g/t gold over 97.99 metres" from hole 26MN-110 at the Goldwedge target. The company emphasizes the "district-scale potential" and consistent high-grade mineralization across multiple targets (Zanzibar Trend, Goldwedge, Black Mammoth). This is a material operational/exploration milestone that would affect a reasonable investor's assessment of the company's mineral resource development progress and the viability of the Manhattan property.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-15
Item 8.01
Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating efficacy (88.9–90.0% of patients reporting improvement at Month 6) with rapid onset and a favorable safety profile including no treatment-related serious adverse events. This material clinical milestone supports advancement toward the Phase 2/3 registration trial (Study '306') with topline data anticipated in 1H 2027.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-15
Item 7.01
NeOnc disclosed receipt of written FDA feedback on the chemistry, manufacturing and controls (CMC) development program for its lead drug candidate NEO212, including specific guidance on formulation, bioavailability studies, and manufacturing requirements. This is a material regulatory milestone for a clinical-stage biotech company that clarifies the path forward for late-stage development of a key asset, though it is not a formal approval or agreement on trial design. The disclosure is operational in nature—relating to drug development strategy and regulatory guidance—rather than financial, governance, or legal.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 1.01
West Pharmaceutical entered into amended and restated technology exchange, cross-license, and distributorship agreements with Daikyo Seiko, Ltd. effective July 14, 2026. These are material commercial agreements governing technology sharing, licensing rights, and distribution arrangements for pharmaceutical packaging products with a 10-year term. While the agreements are substantially similar to prior versions, the formal amendment and restatement of these foundational commercial relationships constitutes a material operational event that does not fit the specific categories of M&A activity, debt issuance, or other defined financial/legal events.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This press release discloses Q2 2026 operational metrics (TCE earnings, revenue days, spot rates) and a material time-charter contract for the VLCC DHT Jaguar at $75,000/day for 3 years commencing September 2026. While the Q2 figures are backward-looking estimates, the new time-charter agreement with a global energy company is a material operational/commercial event affecting the company's fleet employment strategy and forward cash flows. This does not fit earnings_release (no full financial results) or debt_issuance, but rather represents a significant fleet-employment contract that would affect investor assessment of the company's revenue stability and capital allocation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces the launch of a major 2026 drill program at Frontier's Pine Ridge uranium project, a core operational and strategic initiative. The program involves 36,000 meters of drilling across ~120 holes designed to generate a maiden mineral resource estimate by early 2027. While this is a significant operational milestone for an exploration-stage uranium company, it does not fit the specific event categories (M&A, impairment, litigation, debt, etc.); it is a material exploration and development milestone that would affect investor assessment of the company's progress toward commercialization of its flagship asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This exhibit announces the completion of Phase 2 of the No. 3 Shaft modernization program at the Galena Complex, which increases hoisting capacity by 150% (from ~42 stph to 105 stph) and supports planned production growth. The company also discloses two operational incidents: a minor electrical fire at Galena (contained, no injuries, no significant damage) and a regional wildfire near Crescent (no mine damage, brief access disruption). The shaft upgrade is a material operational and strategic milestone supporting the company's growth plans, while the incidents are disclosed as resolved with no material impact on full-year 2026 guidance. This is an operational/strategic business event rather than a discrete financial, governance, or legal event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces Nicola Mining's commencement of gold and silver extraction operations at its Dominion Gold Project, with mill feed extraction expected to commence in early July 2026. The disclosure details completion of key infrastructure (operational camp, excavators, drill attachments, haul truck) and hiring of operational crews. This is a material operational milestone for a junior mining company transitioning from exploration/development to production, affecting investor assessment of the company's near-term cash flow generation and strategic positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This is an exploration update announcing successful completion of drilling and geophysical surveys at Nicola Mining's New Craigmont Copper Project. The disclosure describes technical exploration results (drill hole JT-26-001 confirming porphyry copper target characteristics, Mobile MT geophysical survey, and MMI soil sampling program) that advance the company's exploration model and guide future drilling strategy. While not a discrete M&A, financing, or governance event, this represents a material operational milestone for a junior mining company—the confirmation of a prospective porphyry target and comprehensive technical dataset that positions the company for "aggressive and highly focused exploration program in 2027" would affect a reasonable investor's assessment of exploration success and project value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This exhibit is a monthly operational and financial update disclosing June 2026 bitcoin mining production (64 BTC), cryptocurrency treasury holdings (1,915 BTC and 3,952 ETH), hashrate metrics, and facility efficiency data. While it includes routine operational metrics, the disclosure of record cryptocurrency holdings, joint venture recovery from wildfire disruptions, and strategic updates on hash-to-heat technology deployment and Nasdaq Capital Market transfer constitute material operational and strategic developments affecting investor assessment of the company's mining operations and financial position. The exhibit does not fit discrete event categories (not earnings, not M&A, not exec changes) but represents a material operational update on mining performance and strategic initiatives.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces completion of the first production blast at the Mesabi Metallics iron ore project, a key operational milestone for TMCR's royalty asset. The disclosure is material because it marks the transition from construction to production phase and signals the imminent commencement of royalty revenue generation (anticipated at ~$11 million annually), which is central to TMCR's business model as a royalty financing platform. While not fitting a discrete event category like M&A or earnings, this operational milestone directly affects investor assessment of the Company's path to profitability and cash flow generation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 1.01
Capricor entered into a material lease agreement for approximately 171,000 square feet at 9625 Towne Centre Drive, San Diego, to serve as its new headquarters with expanded manufacturing and R&D facilities. The lease involves approximately $958,000 monthly base rent over a 138-month term with an 18-month rent abatement, representing a significant operational and financial commitment.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
Vistra disclosed results from the PJM Capacity Auction for planning year 2028/2029, clearing approximately 10,924 MW at a weighted average price of $325.00/MW-day across multiple zones. This represents a material operational and financial outcome for a power generation company, as capacity auction results directly affect future revenue streams and market positioning. While not fitting a specific named event type, this is clearly an operational/strategic business milestone that would affect a reasonable investor's assessment of the company's market performance and forward revenue visibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
Tower Semiconductor announces a strategic dual-track capacity expansion in Japan with Government of Japan (METI) support, involving repurposing the Arai facility for 300mm Silicon Photonics and constructing an adjacent new 300mm manufacturing facility. The company updates its 2028 business model to target $3.6 billion revenue and $1.2 billion net profit, with approximately $3 billion in Tower investment net of $1 billion in government grants. This is a material operational and strategic business event involving significant capital investment, facility expansion, and revised financial guidance, but does not fit the specific categories of M&A activity, debt issuance, or other named event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
TAT Technologies announced an expansion of its strategic relationship with Honeywell Aerospace, becoming the sole global authorized distributor of spare parts for the GTCP 331-200/250 APU platform, extending MRO licenses until 2036, and acquiring three APUs for its trading and leasing business. This is a material operational and commercial milestone—a significant partnership expansion and distribution agreement—that does not fit the specific event categories (M&A, debt, equity, litigation, etc.) but clearly affects the registrant's business strategy and revenue prospects in its core aerospace aftermarket segment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
QTREX announced receipt of a commercial purchase order from a leading international government-owned company for customized Shielded RF Monolithic components. The disclosure emphasizes this as a strategic expansion of the company's commercial model into direct supply of proprietary, application-specific components, with production underway and delivery expected within days. While this is a material operational and commercial milestone demonstrating market validation and revenue generation, it does not fit the specific event-type categories (not M&A, not a financial obligation, not a restructuring). This is a material contract/commercial milestone that would affect a reasonable investor's assessment of the company's business trajectory and revenue prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
CleanSpark entered into a 20-year triple-net lease agreement with a high-investment-grade global technology company for 175 MW of data center infrastructure at its Sandersville, Georgia campus, generating $6.6 billion in contracted revenue over the initial term with up to $11.6 billion including extension options, plus an exclusivity arrangement covering its 885 MW Texas portfolio. This represents a transformational operational and strategic milestone for the company's data center business model.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-14
Item 7.01
The disclosure centers on Runway Growth's Q2 2026 portfolio activity and capital allocation strategy, including $85.8 million in new fundings, portfolio composition updates (59 debt and 102 equity investments), and a strategic commitment by the adviser and insiders to purchase up to 10% of outstanding shares over 24 months alongside a $15 million company repurchase program. While the filing includes operational metrics (originations, liquidity events, portfolio construction), the core material event is the capital allocation strategy and insider commitment to share purchases, which is a strategic business decision rather than a discrete financial transaction (debt issuance, M&A, etc.) or governance action. This is material to investors as it signals management confidence and affects capital deployment priorities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
Syndax disclosed an R&D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R&D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
Paramount Gold Nevada Corp. filed a technical report summary for its Grassy Mountain Gold Project prepared in accordance with SEC Regulation S-K subpart 1300. This is a comprehensive feasibility study covering mineral resources, reserves, mining methods, processing, infrastructure, environmental permitting, and economic analysis. While not fitting neatly into standard event categories, this represents a material operational milestone—the completion and disclosure of a detailed technical and economic assessment of a major mining project that would inform investors' understanding of the project's viability and development status.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
ADI Global Distribution is disclosing an investor day event held on July 14, 2026, in connection with its pending spin-off from Resideo Technologies. The filing includes a press release and investor presentation outlining ADI's standalone strategy, financial framework, and medium-term financial targets (4-6% revenue CAGR, >10% Adjusted EBITDA CAGR by 2030, $80M+ in run-rate operating savings). While the spin-off itself is a material M&A activity, this Item 7.01 disclosure focuses on the strategic and operational positioning of ADI as an independent company rather than the separation transaction mechanics, making it primarily an operational/strategic disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for "Treatment of Advanced Metastatic Cancer," which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M&A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces Steakholder Foods' U.S. market entry with its Perfecta™ Premium Plant-Based Meat product line, including the arrival of the first shipment and planned distribution through KeHE Distributors across dozens of retail outlets in the Northeastern USA. This is a material operational and strategic milestone—the company's entry into a major new market with a branded consumer product—but does not fit the specific event categories (M&A, earnings, executive changes, debt, etc.). It represents a significant business development and product commercialization event that would affect a reasonable investor's assessment of the company's growth prospects and market execution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces a framework collaboration agreement with a leading global defense system integrator to supply radar systems for three projects, with initial orders already placed and additional orders anticipated in 2026-2027. The disclosure represents a material operational and commercial milestone—entry into a new high-value vertical (defense/homeland security) beyond automotive, with exclusive radar provider status and demonstrated customer commitment through initial deliveries. While not a discrete M&A transaction, it is a significant strategic partnership and customer win that would affect a reasonable investor's assessment of the company's growth prospects and market expansion.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (>US$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M&A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic analyses, and Phase 2 study findings for an 80 mg BID dose. These data support the company's planned Phase 3 trial design and dose selection, representing a material clinical development milestone for the company's lead drug candidate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
QumulusAI issued fiscal year 2026 guidance disclosing forward ARR of $300 million (~30x growth) and 18 MW of capacity with line of sight to 2.5 GW by 2027. While this resembles an earnings release or forward guidance, it is disclosed under Item 7.01 (Regulation FD Disclosure) as an "investor outlook update" rather than as a formal earnings release tied to quarterly/annual results. The disclosure centers on operational metrics (ARR and capacity expansion) and strategic business outlook rather than historical financial results, making it an operational/strategic disclosure material to investors assessing the company's growth trajectory and infrastructure deployment plans.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
Almonty announced an amendment to its long-term offtake agreement with Global Tungsten & Powders that extends the contract term from 15 to 21 years, increases contracted volumes by 40% to 4.41 million MTU, and improves pricing by 6.3%, resulting in US$490 million in total contracted annual revenue at current pricing. This is a material operational and commercial event—a significant expansion of a key supply contract covering approximately 90% of Phase I production from the Sangdong Mine—that would affect a reasonable investor's assessment of the company's revenue visibility and strategic positioning in the tungsten market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
The filing discloses FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- breast cancer and the company's anticipated commercial launch in late Q3 2026, along with plans to submit a supplemental NDA for PIK3CA-mutated patients. This is a material regulatory milestone and product approval event that does not fit neatly into the standard financial, governance, or legal categories—it is primarily an operational/strategic business milestone involving regulatory approval and commercialization of the company's lead product candidate.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This announcement discloses completion of a technical field scouting program and planned geophysical survey on the M47 exploration licence in Türkiye. The disclosure describes operational exploration activities—geological validation, gravity studies, and planned seismic acquisition—that advance the company's development of a material asset (a 29% working interest with US$15 million funding commitment). While the event is clearly operational and strategic in nature, it does not fit the specific named categories (no M&A, no workforce reduction, no material contract announcement per se). The materiality derives from the company's focus on this block and the resource potential previously disclosed (27.6 MMbbl contingent resource with US$733.5M NPV-10), making exploration progress on this asset material to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This press release announces an amendment to the M47 Farm-In Agreement that restructures and extends payment obligations under Trillion's earn-in commitment for a 29% participating interest in an onshore oil exploration block in Türkiye. The amendment extends the next tranche payment deadline to September 15, 2026 (approximately USD$4.35 million) and postpones further payments until September 2027, providing material financial flexibility. While the core transaction (the farm-in agreement itself) was previously disclosed in January 2026, this amendment materially alters the payment schedule and timing of the Company's financial commitments, which is operationally and strategically significant for an exploration company managing cash flow and development timelines.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
Talen Energy announced results from the PJM Base Residual Auction for 2028/2029, clearing 10,180 megawatts at $325/MW-day, equating to approximately $1.208 billion in capacity revenues. This is a material operational and commercial milestone for an independent power producer, reflecting successful capacity procurement in a key wholesale market, but does not fit the specific categories of earnings release, debt issuance, M&A, or other named event types. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02 (Results of Operations), and represents a significant commercial achievement rather than periodic financial results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 7.01
Baxter disclosed a material reorganization of its reportable segments effective Q2 2026, consolidating from three segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals) to two (MPT and HST), with the former Pharmaceuticals segment now nested within MPT's Infusion Therapies & Platforms division. The company also updated corporate cost allocation methodology. While the filing explicitly states this does not constitute a restatement and does not affect consolidated net income, EPS, total assets, or stockholders' equity, the segment restructuring reflects a fundamental change in how the chief operating decision maker allocates resources and assesses performance—a material operational and strategic realignment that would affect investor analysis of business performance and comparability across periods.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
Guardian Metal Resources disclosed exploration results and updates across its non-core Nevada-based tungsten and precious-metal project portfolio, including newly acquired projects (White Elephant, Cinch) and expanded claims at existing projects (Pilot North, Garfield). The company announced significant assay results and claim staking activities. While these are exploration-stage results rather than a discrete operational event like a contract award or partnership, the disclosure of material exploration results across multiple projects and the company's strategic assessment of options for these assets (including potential monetization) constitute a material operational update affecting investor assessment of the company's asset base and strategic direction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
This press release discloses multiple strategic business developments: continued government engagement with BARDA, NIAID, AFRRI, and DoW on ARS preparedness; a 200-fold manufacturing scale-up at Velocity Bioworks; and planned expansion into oncology supportive care. These are operational and strategic milestones rather than financial results, M&A activity, or governance changes. While the filing is under Item 7.01 (Regulation FD Disclosure) rather than a dedicated 8-K item, the substance reflects material operational progress across regulatory, manufacturing, and clinical development initiatives that would affect a reasonable investor's assessment of the company's strategic positioning and value creation pathways.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
Curaleaf announced that exchange-traded options on its shares are commencing trading on the Montréal Exchange, an exchange-initiated listing that reflects the company's market maturity and institutional relevance. While this is a capital markets milestone, it is not a discrete M&A, financing, or governance event; rather, it is an operational/strategic development that enhances market infrastructure around the company's equity. The company explicitly states it did not apply for the listing and does not control it, and the listing involves no issuance of securities or proceeds to the company. This is material to investors as it expands available trading strategies and liquidity, but it is best classified as an operational milestone rather than a specific financial or governance event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
Curaleaf announced that Spain's AEMPS has approved registration of two standardized cannabis preparations (THC-dominant and CBD-dominant) developed by its Spanish subsidiary, making Curaleaf the first company to register under Spain's new Royal Decree 903/2025 framework. This is a material regulatory milestone that opens a pharmaceutical-grade distribution pathway through hospital pharmacies in a major European market (50 million people), reinforcing the company's strategic position in regulated international cannabis markets and supporting its long-term growth in Europe.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
The disclosure reports results of the PJM capacity auction for 2028-2029, showing that all of Constellation's power plants cleared with 18,875 MW of total capacity at $325/MW. This is a material operational and financial event affecting future revenue streams, particularly for nuclear units whose capacity revenues factor into Production Tax Credit calculations. While not a traditional M&A, litigation, or governance matter, the auction results represent a significant market outcome affecting the company's operational and financial planning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-14
The filing discloses a change in special servicer for the Christiana Mall mortgage loan within the BBCMS 2018-CHRS securitization, effective July 14, 2026. Green Loan Services LLC replaces Trimont LLC as special servicer at the direction of Marathon Asset Management, the directing certificateholder. This is an operational/administrative change to loan servicing arrangements that would be material to investors in the securitization trust, as the special servicer's identity and performance directly affect loan administration and potential workout outcomes.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
The disclosure announces a new time charter agreement for the vessel Mount Aconcagua for 16–18 months at an index-linked rate with a premium to the Baltic 5TC index and conversion rights to fixed rates. This is a material operational and commercial contract for a bulk carrier company, affecting vessel utilization and revenue generation, but does not fit the specific event categories (M&A, debt, equity issuance, etc.). It is clearly an operational/commercial milestone rather than a routine administrative matter.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 8.01
PSCo filed a natural gas rate case seeking $190 million in revenue increase, and on July 13, 2026, a comprehensive non-unanimous settlement agreement was filed with the CPUC reducing the request to $123 million (7.5% increase) with a 9.2% ROE. This is a material regulatory milestone affecting PSCo's revenue and cost recovery, with final rates anticipated in Q4 2026. While regulatory proceedings are operational in nature, this settlement represents a significant business outcome that would affect investor assessment of the company's financial trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 7.01
Energy Fuels disclosed an investor presentation regarding expansion of its critical materials operations, including strategic initiatives in rare earths, uranium, and heavy mineral sands, as well as pending acquisitions (VAC and ASM). This is a material operational and strategic disclosure under Regulation FD, but does not fit a specific event category—it is neither a discrete M&A completion, earnings release, nor a single operational milestone, but rather a comprehensive strategic update on multiple business lines and growth projects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-13
EX-99.1
This press release discloses multiple material operational and development milestones for Vertical Aerospace's eVTOL aircraft program: successful piloted transition flights (described as "the most significant technical milestone in its history"), receipt of an expanded Permit to Fly from the UK CAA, completion of Critical Design Review by end of 2026, and a revised Type Certification timeline to 2029 (delayed from the previously indicated 2028 target). While the disclosure includes strategic partnerships and pre-order information, the core substance is operational progress on aircraft development and regulatory certification—a material update to investors on the company's path to commercialization that does not fit neatly into a single named event category but is clearly operational in nature.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 7.01
Armata announced FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, which the company characterizes as "an important regulatory milestone" on the path toward a future BLA. This is a material operational/regulatory milestone in the drug development process—it establishes the agreed framework for pediatric studies and is a prerequisite for BLA submission. While not a specific named event type (not earnings, M&A, impairment, etc.), it is clearly material to investors assessing the company's clinical development progress and regulatory pathway for its lead candidate.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-13
EX-99.1
This exhibit is a corporate presentation detailing Origin Agritech's turnaround strategy, leadership changes, R&D pipeline, and commercialization roadmap. While it includes executive appointments (CEO Weibin Yan in August 2024, CFO Dr. James Chen and Board member Dr. Jian Zhang in March 2026), the primary focus is on operational and strategic initiatives—market-oriented breeding, biotech commercialization, sales network rebuilding, supply chain upgrades, and a multi-year growth strategy (2024–2032). The disclosure emphasizes operational transformation and product development rather than discrete executive events. This is material to investors assessing the company's turnaround execution and competitive positioning in China's seed industry.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-13
Item 8.01
Alto Neuroscience announced acceleration and expansion of clinical development for ALTO-207, including an additional Phase 3 trial for treatment-resistant depression, representing a material strategic decision affecting the company's development trajectory and capital allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 7.01
Astrana Health disclosed 2024 ACO performance results showing $120.4 million in gross shared savings across all eight affiliated ACOs, with specific metrics on Medicare beneficiaries served and rankings. While this is operational performance data rather than a formal earnings release (which would typically be Item 2.02), the disclosure of material business performance metrics—particularly the company's core value-based care platform results—constitutes a significant operational event that would affect investor assessment of the company's strategic execution and competitive positioning in the healthcare market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 8.01
Ocugen announced a binding term sheet to license OCU400 for retinitis pigmentosa in the Middle East and North Africa region, with cumulative sales milestones up to $255 million, upfront/development payments up to $4 million, and 22% royalties on net sales. This is a material strategic partnership and licensing arrangement that expands the company's geographic reach and revenue potential, but does not constitute a traditional M&A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant commercial partnership—rather than fitting the specific M&A definition.
View raw filing on EDGAR →